The efficacy and safety of hybrid ablations for atrial fibrillation, assessed using implantable ECG recorders and sequential magnetic resonance imaging

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
P Osmancik ◽  
D Herman ◽  
P Kacer ◽  
V Rizov ◽  
J Vesela ◽  
...  

Abstract Background Treatment strategies for patients with non-paroxysmal atrial fibrillation (AF) still do not provide satisfactory results. In pursuit of better results, other approaches, such as the hybrid ablation (i.e., thoracoscopic epicardial ablation followed by catheter ablation), have been used. The accurate data regarding the efficacy and safety of the procedure are still limited. Purpose To determine the procedural safety, and the mid-term efficacy of hybrid ablation. Methods Patients with non-paroxysmal AF were included. They underwent thoracoscopic, off-pump ablation using the COBRA Fusion radiofrequency system, followed by a percutaneous catheter ablation (2.6±1.0 mo after surgery). Sequential cerebral magnetic resonance imaging (MRI) was done (1 day before and 3–5 days after surgery) to look for new ischemic lesions in the brain. Implantable loop recorders (ILR) were implanted 1–3 days after the thoracoscopic procedure. Rhythm outcomes were defined as (1) AF-free OFF survival (i.e., no single episode of AF or atrial tachycardia (AT) lasting >30 sec as assessed using ILR, remaining OFF anti-arrhythmic drugs (AADs) and without a redo ablation or cardioversion), (2) AF-free ON survival (i.e., recurrence of AF or AT, however, AF freedom with no more AF/AT episodes >30 sec was achieved through re-initiation AADs, re-ablation, or cardioversion), and (3) rhythm control survival (repeated self-terminated paroxysms of AF/AT despite AADs, re-ablation, or cardioversion). Rate control strategy (i.e. the presence of AF with no more attempts for SR reinitiation) was considered as failure of the procedure. Results Sixty patients were enrolled, 37 (62%) were men, the mean age was 62.6±10.5 years, 29 (48%) with long-standing persistent AF. Thoracoscopic ablation was successfully performed in 56 (93.3%) patients, and significant complications occurred in 7 (11.8%) patients. Fifty-three patients (88.3%) underwent a pre- and 47 underwent a control postoperative cerebral MRI. Chronic ischemic brain lesions were present in 36 (68%) patients on the pre-operative MRI. New ischemic brain lesions on the post-operative MRI were seen in 19 (40%) patients, 18 of whom were without neurological symptoms, 1 patient had a manifest stroke. Catheter ablations were carried out in all 60 patients without complications. The mean follow-up was 22.9±10.3 months. AF-free OFF survival was present in 53.4% at 1 and in 41.5% at 2 years. AF-free ON survival was present in 72% at 1 year and 62% at 2 years. Rhythm control survival was present in 91% at 1 year and 89% at 2 years. Only 9%, or 11% of patients were on rate control at 1 and 2 years, resp. Conclusions Hybrid ablation presents an effective treatment strategy for patients with non-paroxysmal AF. The thoracoscopic part of the hybrid ablation procedure is accompanied by a high risk of silent cerebral ischemia, which should be considered in patients referred to this procedure. Funding Acknowledgement Type of funding source: Public grant(s) – National budget only. Main funding source(s): Research grant of the Ministry of Health of the Czech Republic, Nr. 16-32478A

2020 ◽  
Vol 10 (4) ◽  
pp. 382-386
Author(s):  
Qurain Alshammari ◽  
Mohammed Salih ◽  
Moawia Gameraddin ◽  
Bushra Abdelmalik ◽  
Sultan Alshoabi ◽  
...  

Background: Type 2 diabetes mellitus (T2DM) and hypertension (HTN) are risk factors for the spectrum of brain lesions. In this paper, we studied the impact of T2DM and HTN on the incidence of several brain lesions diagnosed with magnetic resonance imaging (MRI). Methods and Results: This retrospective, single-center study was conducted at Royal Care International Hospital (Khartoum, Sudan) from January 2016 to December 2016 and included 80 patients (40 male and 40 female, aged between 20 years and 90 years) with suspected brain disorders. MRI brain examinations were conducted on a 1.5 Tesla MRI system (Toshiba Medical Systems, Tokyo, Japan). The following sequences were analyzed: T1-weighted imaging (T1WI), T2-weighted imaging (T2WI), fluid-attenuated inversion recovery (FLAIR), and diffusion-weighted imaging (DWI). Brain lesions were characterized by magnetic imaging spectroscopy and histopathological analysis. Binary logistic regression analysis was used to establish a mathematical model of the relationship between T2DM/HTN and the prevalence of brain lesions. Among 80 patients, HTN, T2D, and the combination of T2D and HTN were identified in 18(22.5%), 9(11.2%), and 11(13.8%) patients, respectively. Brain lesions were found in 48(60%) patients and were most prevalent in the age group of 66-80 years. The brain lesions included ischemic brain infarction (IBI) (22.5%), brain tumors (11.2%), cerebral hemorrhages (6.2%), brain atrophy (BA) (1.2 %), IBI with BA (16.2%), and brain metastases (2.5%). Regression analysis showed that HTN and T2DM were associated with significantly higher ORs for brain lesions ([OR=2.459, 95% CI: 1.673–3.614, P<0.001] and [OR=1.507, 95% CI: 1.067–2.128, P= 0.042], and [OR=1.078, 95% CI:1.033–1.124, P=0.001], respectively). HTN was associated with significantly higher OR for ischemic brain infarction (OR=7.404, 95% CI: 2.600–21.081, P<0.001). Conclusion: The study showed a significant interaction between HTN and T2DM on the prevalence of brain lesions, especially ischemic brain infarction and brain atrophy.


2003 ◽  
Vol 23 (11) ◽  
pp. 1356-1361 ◽  
Author(s):  
Christoph Kleinschnitz ◽  
Martin Bendszus ◽  
Marco Frank ◽  
Laszlo Solymosi ◽  
Klaus V Toyka ◽  
...  

Although macrophages represent the major inflammatory cells in cerebral ischemia, the kinetics of macrophage infiltration are largely unknown. To address this issue, we injected superparamagnetic iron oxide (SPIO) particles into the circulation of rats at different time points after focal photothrombotic cerebral infarction and performed magnetic resonance imaging (MRI) 24 hours later. Infarcts appeared as hyperintense lesions on T2-w and CISS MR images during all stages. At days 5.5 and 6, an additional rim of signal loss indicative of local accumulation of SPIO particles appeared at the outer margin of the hyperintense ischemic lesions, which was not present at days 1 to 5. Areas of signal loss corresponded to local accumulation of iron-loaded macrophages in histologic sections. At day 8, signal loss became restricted to the inner core of the lesions and ceased thereafter. Macrophages, however, were still present in late ischemic brain lesions, but they were iron-negative. Thus SPIO-induced signal loss indicates active macrophage transmigration into ischemic infarcts but not their mere presence. SPIO-induced signal loss was independent from the disturbance of the blood-brain barrier. In conclusion, we have shown by in vivo monitoring that macrophages enter photothrombotic infarcts at late stages of infarct development, suggesting a role in tissue remodeling rather than neuronal injury.


2019 ◽  
Vol 32 (3) ◽  
pp. 166-172 ◽  
Author(s):  
Seyed Mohammad Seyedsaadat ◽  
Leonardo Rangel Castilla ◽  
Giuseppe Lanzino ◽  
Harry J Cloft ◽  
Daniel J Blezek ◽  
...  

Objectives Remote ischemic preconditioning has been proposed as a possible potential treatment for ischemic stroke. However, neuroprotective benefits of the pre-procedural administration of remote ischemic preconditioning have not been investigated in patients undergoing an elective endovascular intracranial aneurysm repair procedure. This study investigated the safety and feasibility of remote ischemic preconditioning in patients with an unruptured intracranial aneurysm who undergo elective endovascular treatment. Methods In this single-center prospective study, patients with an unruptured intracranial aneurysm undergoing elective endovascular treatment with flow diverters or coiling were recruited. Patients received three intermittent cycles of 5 minutes arm ischemia followed by reperfusion using manual blood cuff inflation/deflation less than 5 hours prior to endovascular treatment. Patients were monitored and followed up for remote ischemic preconditioning-related adverse events and ischemic brain lesions by diffusion -weighted magnetic resonance imaging within 48 hours following endovascular treatment. Results A total of seven patients aged 60 ± 5 years with an unruptured intracranial aneurysm successfully completed a total of 21 sessions of remote ischemic preconditioning and the required procedures. Except for two patients who developed skin petechiae over their arms, no other serious procedure-related adverse events were observed as a result of the remote ischemic preconditioning procedure. On follow-up diffusion -weighted magnetic resonance imaging, a total of 19 ischemic brain lesions with a median (interquartile range) volume of 245 (61–466) mm3 were found in four out of seven patients. Conclusions The application of remote ischemic preconditioning prior to endovascular intracranial aneurysm repair was well tolerated, safe and clinically feasible. Larger sham-controlled clinical trials are required to determine the safety and efficacy of this therapeutic strategy in mitigating ischemic damage following endovascular treatment of intracranial aneurysms.


2017 ◽  
Vol 23 (14) ◽  
pp. 1909-1917 ◽  
Author(s):  
Krzysztof Selmaj ◽  
Frederik Barkhof ◽  
Anna N Belova ◽  
Christian Wolf ◽  
Evelyn RW van den Tweel ◽  
...  

Background: Open-label 15-month follow-up of the double-blind, placebo-controlled Glatiramer Acetate clinical Trial to assess Equivalence with Copaxone® (GATE) trial. Objective: To evaluate efficacy, safety, and tolerability of prolonged generic glatiramer acetate (GTR) treatment and to evaluate efficacy, safety, and tolerability of switching from brand glatiramer acetate (GA) to GTR treatment. Methods: A total of 729 patients received GTR 20 mg/mL daily. Safety was assessed at months 12, 15, 18, 21, and 24 and Expanded Disability Status Scale and magnetic resonance imaging (MRI) scans at months 12, 18, and 24. The presence of glatiramer anti-drug antibodies (ADAs) was tested at baseline and months 1, 3, 6, 9, 12, 18, and 24. Results: The mean number of gadolinium-enhancing lesions in the GTR/GTR and GA/GTR groups was similar at months 12, 18, and 24. The change in other MRI parameters was also similar in the GTR/GTR and GA/GTR groups. The annualized relapse rate (ARR) did not differ between the GTR/GTR and GA/GTR groups, 0.21 and 0.24, respectively. The incidence, spectrum, and severity of reported adverse events did not differ between the GTR/GTR and GA/GTR groups. Glatiramer ADA titers were similar in the GTR/GTR and GA/GTR groups. Conclusion: Efficacy and safety of GTR is maintained over 2 years. Additionally, switching from GA to GTR is safe and well tolerated.


Stroke ◽  
2012 ◽  
Vol 43 (12) ◽  
pp. 3266-3270 ◽  
Author(s):  
Margherita Cavalieri ◽  
Reinhold Schmidt ◽  
Christopher Chen ◽  
Vincent Mok ◽  
Gabriel R. de Freitas ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document